Novartis

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

Novartis pays $800M to buy Regulus for phase 3-ready kidney drug

If approved, Regulus' farabursen will enter a market already served by Otsuka’s Jynarque.
Nick Paul Taylor Apr 30, 2025 9:30am
Broom sweep clean

Novartis axes osteoarthritis asset and radioligand therapy

Apr 29, 2025 5:24am
X ray illustration of a running person with pain in knee joint with blue background

Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset

Apr 16, 2025 2:55pm
The Top Line

A closer look at pharma's top R&D budgets

Apr 4, 2025 9:34am
parachute chutes

FDA rocked by leadership shake-ups—Chutes & Ladders

Apr 4, 2025 8:30am
A representation of golden gas or oil pipes surrounded with coins on financial graph with candle bars

Top 10 pharma R&D budgets in 2024

Mar 31, 2025 6:00am